Biogen's Stock Slumps as Biosimilars Hit MS Sales and Alzheimer Setbacks Loom

Why It Matters

Biogen’s challenges illustrate a broader inflection point for legacy biotech firms that rely heavily on aging blockbuster drugs. As biosimilars proliferate, companies must accelerate innovation pipelines and secure differentiated delivery methods to maintain pricing power. The Alzheimer’s market, already fraught with high failure rates, adds another layer of uncertainty; Biogen’s ability to grow Leqembi could set a benchmark for how co‑developed therapies navigate commercial adoption. The company’s trajectory also has implications for investors seeking exposure to neuro‑degenerative disease treatments. A sustained decline in Biogen’s revenue could trigger sector‑wide re‑pricing, prompting fund managers to reassess exposure to firms with similar product mixes. Conversely, a successful rollout of newer assets could reaffirm the viability of a diversification strategy that blends legacy revenue with targeted, high‑margin launches.

Key Takeaways

• Biogen reported 2025 revenue of $9.9 billion, up 2% YoY, while adjusted EPS fell 7% to $15.28.
• Leqembi’s revenue rose 197% YoY to $178 million after gaining subcutaneous maintenance approval.
• Biosimilar competition is eroding market share in Biogen’s multiple sclerosis franchise.
• Guidance projects a year‑over‑year revenue decline for 2026, heightening investor risk.
• New products Skyclarys and Zurzuvae received regulatory approval, offering potential growth avenues.

Pulse Analysis

Biogen’s current predicament underscores the accelerating pace at which biosimilars are reshaping the neurology market. Historically, MS therapies commanded premium pricing due to limited alternatives, but the entry of lower‑cost biologics is compressing margins and forcing incumbents to innovate on delivery and dosing schedules. Biogen’s high‑dose Spinraza formulation, which reduces the number of initial doses, is a tactical response that may buy time, but it does not address the fundamental pricing pressure.

The Alzheimer’s segment presents a different set of challenges. Leqembi’s rapid revenue growth reflects strong physician and patient interest in a subcutaneous option, yet the therapy still competes in a crowded field where payer skepticism remains high. Co‑marketing with Eisai mitigates some risk, but the partnership also dilutes revenue capture. If Biogen can secure approval for subcutaneous initiation, it could unlock a larger addressable market, but the path to widespread adoption will depend on real‑world efficacy data and reimbursement negotiations.

Looking forward, Biogen’s ability to orchestrate a turnaround will hinge on execution across three fronts: scaling newer product launches, managing biosimilar competition through differentiated formulations, and delivering pipeline candidates that can become the next revenue anchors. The company’s acquisition strategy, while expanding its pipeline, adds integration complexity that could distract from these core imperatives. Investors should watch the 2026 earnings guidance closely; a deviation—positive or negative—will likely trigger a decisive market reaction, setting the tone for biotech valuations in the neuro‑degenerative space.